A Phase II Trial of Pembrolizumab Plus Lenvatinib for the Treatment of Patients With Advanced Uterine and Ovarian Carcinosarcomas
Latest Information Update: 03 May 2023
At a glance
- Drugs Lenvatinib (Primary) ; Pembrolizumab (Primary)
- Indications Carcinoma; Sarcoma; Uterine cancer
- Focus Therapeutic Use
- 28 Apr 2023 Planned End Date changed from 23 Dec 2023 to 23 Dec 2024.
- 28 Apr 2023 Planned primary completion date changed from 23 Dec 2023 to 23 Dec 2024.
- 29 Dec 2021 Planned End Date changed from 1 Nov 2023 to 23 Dec 2023.